Market Overview

UPDATE: Goldman Sachs Maintains Neutral Rating on ViroPharma, Lowers PT


Goldman Sachs reduced their Viropharma (NASDAQ: VPHM) estimates following a release of generic versions of their drug Vanco.

Goldman Sachs went on to say, “…we are reducing our VPHM estimates for 2012-2015. This drives a decrease in our 12-month price target, equally based on our DCF/SOTP analyses, to $22 from $26.”

VPHM closed yesterday at $22.44.

Posted-In: Goldman SachsAnalyst Color Reiteration Analyst Ratings


Related Articles (VPHM)

View Comments and Join the Discussion!